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Sickle Cell Disease (SCD) occurs commonly in sub- Saharan African region. For instance, out of the 
estimated 305,800 babies born annually with SCD worldwide about 75% occurred in sub-Saharan Africa 
(SSA). Vasoocclusive painful crisis is the prototype clinical event among SCD patients with nearly all SCD 
persons experiencing the episode during their lifetime. Additionally, acute vasooculusive pain crises may 
eventually progressed to chronic pain, resulting in poor quality of life associated with other morbidities, 
including anxiety, depression and dependence on pain medications. Transformation and technological 
development that brought about new clinical approaches and treatments have increased rates of survival in 
patients with Sickle Cell Disease (SCD). However, the overall life expectancy of such patients remains 
shorter than other normal populations. Therefore, management of pain should be guided by an 
individualized précised prescribing and monitoring protocol. To this end, the concept of precision medicine 
that is predicated on using practical application of human genomics provide an evolving set of translational 
research goals in the management of pain in sickle cell disease. This review tend to shed light on this new 
concept, hoping that the review will facilitate improved and more accessible care for all patients leaving with 
sickle cell disease. 
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INTRODUCTION 
Sickle cell disease (SCD) was first reported by 
Herrick in 1910 (Herrick JB. 1910). Since then 
substantial knowledge about SCD has been 
acquired. It is a single amino acid inherited 
disorder of a nucleotide mutation, resulting from 
amino acid substitution from glutamic acid to 
valine at position 6 on the β-globin subunit. This 
mutation causes hemoglobin S (HbS) to 
polymerizes, resulting in sickling of erythrocyte 
that becomes more rigid, with the consequent 
expression of various cellular adhesion molecules 
(Bunn, 1997; Ballas and Mohandas, 2004). 
 
Sickle cell disease is one of the most common 
inherited blood disorders affecting millions of 
people globally in humans and is associated with 
myriad complications in Humans (Piel et al., 
2017, Kato et al., 2018). Sickle cell disease is a 
single amino acid substitution in the β-globin 
chain that lead to formation of  mutant 
hemoglobin S (HbS) which can polymerize in red 
cells under certain conditions, resulting in a 
complex cascade of processes that include but 
not limited to erythrocyte sickling, intravascular 
hemolysis, increased adhesion of red cells to the 
endothelium of blood vessels, activation of 
platelets, production of inflammatory cytokines, 
and subsequently result in vascular occlusion 
(Ware et al., 2017). Repeated hemolysis and 
anemia result in vascular damage and tissue 
hypoxia, which may lead to multiorgan damage 
and an increased risk of death (DeBaun et al., 
2012; Nath and Hebbel, 2015; Gladwin, 2016; 
Kato et al., 2017). Early detection, ideally by 
means of screening and institution of preventive 
measures may save lives. For almost two 
decades now, only two medications approved by 
the Food and Drug Administration are available 
(hydroxyurea and l-glutamine [USAN, glutamine]) 
(Niihara et al., 2018). 
 
Although research findings reported beneficial 
effect of hydroxyurea (Nevitt et al., 2017),  in 
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reducing frequencies of hospital admissions for 
painful crisis among sickle cell diseases patients, 
use of the agent remains low especially in 
resource limited societies and chronic medical 
complications and early death in persons with 
sickle cell disease remain a substantial burden. In 
particular, chronic organ dysfunction has become 
a leading cause of death in adults with sickle cell 
disease in the United States (Lanzkron et al. 
2013; Vichinsky, 2017).  Additionally, 
hematopoietic stem cell transplantation, the only 
possible curative therapy, has been used in only 
developed, economically advantage nations, 
covering a small fragment of affected patients. 
 
Clinico-Pathological Features of Sickle Cell 
Disease 
Vasoocclusive painful crisis is the prototype of 
acute complications of sickle cell disease, with 
nearly all SCD persons experiencing a 
vasoocclusive crisis during their lifetime. The 
initial crisis usually occur during childhood, often 
presenting as dactylitis, and subsequently with 
variable frequency, affecting the extremities, 
chest, and back (Ballas and Lusardi, 2005; 
Jacob, 2005; Smith et al., 2008). Therefore, 
attending physicians should clearly understand 
and appreciate the severe nature of the pain and 
the urgent need for effective therapies. Sickle cell 
disease patients presenting with a vasoocclusive 
crisis are at high risk of other well defined acute 
complications such as acute chest syndrome 
(ACS), which can rapidly progressed to 
respiratory failure and requires immediate 
evaluation and effective management with 
antibiotics, oxygen and blood transfusion. 
 
The painful crisis may result from avascular 
necrosis of bone marrow and the source of the 
pain is presumed to be an increased 
intramedullary pressure consequent on the 
ensuing inflammatory process. The pathological 
evidence implicating bone marrow necrosis in 
painful crisis include: (a) presence of necrotic 
marrow on aspiration from sites of pains (b) Bone 
scintigraphic evidence of increased calcium 
turnover (c) Magnetic Resonance Imaging (MRI) 
evidence of acute infarction and edema (d) 
Confinement of pain to the site of active bone 
marrow with occasional evidence of myonecrosis 
and myofibrosis (Graham and Bonyl, 2001). 
Other less common complications include acute 
cholecystitis, hepatobiliary complications, acute 
splenic sequestration, priapism, acute kidney 
injury, acute aplastic crisis infection and stroke. 
These other acute complications of SCD require 
effective management that is better guided by 
pharmacogenetics.  
 
Some of the above mentioned acute 
complications of SCD such as stroke, may not 
resolve completely but rather, evolve into sub-
acute or chronic phases that require special 
attention and approaches to management 
(Diatchenko et al., 2005). For instance, sickle cell 
acute pain crises may eventually progressed to 
chronic pain, resulting in poor quality of life 
(Embury, 1994; Bellet et al., 1995; Dampier, 
2002; Ballas et al., 2010), associated with other 
morbidities, including loneliness, anxiety, 
depression, despair, insomnia, and dependence 
on pain medications (Benjamin et al., 1999; 
Serjeant and Serjeant, 2001; Adams and 
Brambilla, 2005). On the other hand chronic 
complications of SCD can evolve gradually during 
the lifespan of affected persons.  
 
Chronic complications such as avascular 
necrosis, occurs in about one out of ten sickle cell 
disease patients, and the hip joint is the most 
common area affected (Milner et al., 1991). This 
complication often causes chronic severe pain 
and disability. Therapy is usually conservative, 
although, surgical approach in form of joint 
replacement may be necessary. 
 
Pulmonary Arterial Hypertension due to 
restriction and stiffness of the walls of pulmonary 
artery may resulting in elevation of mean 
pulmonary arterial pressure (>25 mm Hg at rest). 
This complication is an independent risk factor for 
mortality in SCD (Parent et al., 2011). 
 




Chronic kidney disease, may be seen in about 
4%to 18% of persons with SCD (Ataga and 
Orringer, 2000). In a study in US, renal failure 
was reported in 4.2%of persons with SCA. 
Additionally, among those developing renal 
failure, 68% previously had proteinuria, 40% had 
nephrotic syndrome, and 33% had hypertension 
(Powars et al., 1991). 
 
Chronic leg ulcers are other form of long-term 
vascular complication seen among sickle cell 
disease patients and are treated with standard 
therapy as well as evaluation for venous 
etiologies. Antibiotic therapy is reserved for ulcers 
with culture-proven bacterial infection. When 
ulcers are persistent, coexistence of osteomyelitis 
should be assessed. 
 
Management of pain in Sickle Cell Disease 
It is particularly important that, pain management 
should include strategies employed to control 
attack in a timely manner, guided by an 
individualized prescribing and monitoring protocol 
(Bellet et al., 1995). Transformation and 
technological development that brought about, 
new clinical approaches and treatments have 
increased rates of survival in patients with SCD 
(Gaston et al., 1986; Adams. et al 1989; Adams 
and Brambilla. 2005). However, the overall life 
expectancy of such patients remains shorter than 
other normal populations, largely accounted for 
by both acute and chronic complications of SCD 
(Kochanek et al., 2011; Sheth et al., 2013). 
 
As far back as about four decade ago, 
hydroxyurea was identified as a promising drug 
candidate for SCD by increasing fetal hemoglobin 
levels. Since then oral daily dose hydroxyurea 
therapy has been shown to reduce many acute 
and chronic complications of SCD (Paule et al., 
2011). Additional mechanisms through which 
hydroxyurea mitigate acute and long-term 
complications of sickle cell disease include: 
reducing the quantity of circulating red blood and 
white blood cells, decreasing cellular expression 
of adhesion molecules, (thereby reducing 
vasooculusion) (Ware, 2010). Hydroxyurea also 
increases mean corpuscular volume of 
reticulocytes and by extension improves cellular 
deformability, which in turn increases blood flow 
and reduces vasoocclusion. Furthermore, nitric 
oxide released by hydroxyurea metabolism may 
lead to vasodilation (King, 2004). Therefore, oral 
daily hydroxyurea treatment substantially reduces 
the number and severity of painful episodes 
(Charache et al., 1995). More importantly, Long-
term hydroxyurea therapy may results in a 
reduction in mortality (Steinberg et al., 2003; 
Voskaridou et al., 2010). 
 
Possible Role of Precision Medicine in 
Managing Vasooculusive Pain Crisis  
Precision medicine as a continuous fundamental 
process that aims to improve the effectiveness 
and efficiency of clinical practice, through better 
understanding of how the unique biological 
characteristics of patients and their social or 
environmental factors influences their health and 
disease, holds strong potentials to transform 
quality of pain management and improve patient 
outcomes among individuals with sickle cell 
disease. The drivable benefits for patients and 
the healthcare delivery system include: more 
precise diagnosis and prognosis, well targeted 
and personalized interventions, as well as good 
understanding and prediction of individual 
disease risk. All these could summon to more 
efficient and effective use of healthcare delivery 
system resources, especially in resource limited 
societies, such as Sub-Saharan Africa. 
Furthermore, Precision medicine provide a 
unique opportunity to move away from a one size 
fits all approach to the management and care of 
patients with pain crises, to one which uses new 
approaches that better manage patients' 
background condition and target therapies to 
achieve the best outcomes in the management of 
a patient's disease or predisposition to disease. 
 
Use of Opioids Analgesics 
One of the most interesting developments in 
basic science related to practical application of 
precision medicine is the progress so far made in 
understanding the pharmacodynamics and 
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pharmacokinetics of opioids. Foremost among 
these was the mechanism of action of opioids in 
relieving pain. In the 1970s, it was hypothesized 
that opioids have receptors to bind and activate in 
order to relieve pain by blocking or minimizing the 
transmission of painful stimuli and raising the 
pain threshold (Voskaridou et al., 2010). It did not 
take long after that to identify opioids as ligands 
that bind to saturable receptors in the central 
nervous system (Beckett and Casy.1954; Pert 
and Snyder,1973). It was reported that, the 
binding affinity of opioids to its receptors varies 
considerably and that, the binding affinities of 
opioids correlate with their analgesic potencies 
(Kosterlitz,1975; Snyder,1984). At the molecular 
level it was found that, opioids initiate chain 
reactions that include but not limited to: activation 
of G proteins, inhibition of adenylate cyclase, and 
extrusion of potassium ions, leading to 
hyperpolarization, which in turns delays 
transmission of painful stimuli (Herz, 1971; 
Martin,1976; Snyder,1977; Simon and 
Hiller,1978; Ballas, 2015).  
 
Additionally, advancement in understanding the 
pharmacokinetics of opioids metabolism revealed 
the role of CYP enzymes and uridine diphosphate 
glucuronyltransferase (UGT) enzymes in 
Glucuronidation of opioids, as well as the 
cytochrome P450 isoenzyme system. The net 
effect of opioid analgesics depends on the 
availability of these enzyme(s) to convert it into 
metabolites. For instance, the CYP2D6 
genotypes are categorized into phenotypes with 
Ultrarapid metabolizers (UMs) having greater 
than normal activity due to duplication or 
triplication, of active alleles, extensive 
metabolizers (EMs) have normal enzyme activity, 
while intermediate metabolizers (IMs) have 
decreased enzyme activity, and poor 
metabolizers (PMs) have absent or little enzyme 
activity (Sery et al., 2005; Shord et al., 2009; 
Neafsey, 2009; McGregor et al. 2012). Therefore, 
Patients who are UMs of some opioids like 
fentanyl would rapidly convert it into inactive 
metabolites with minimal or absent analgesic 
effect requiring increasing the dose of fentanyl. 
On the other hand, patients who are PMs of 
fentanyl would experience prompt relief with 
relatively small doses of fentanyl but higher 
doses could be toxic due to the accumulation of 
unmetabolized fentanyl (Lotsch et al., 2004). With 
these observations, it is obvious that, 
technological development and better 
understanding of pharmacodynamics and 
pharmacokinetics of opioids demonstrate 
variability of genotypes among sickle cell disease 
patients and even more variability in individual 
responses to opioids. Therefore, evaluating the 
pharmacogenetics profile of each patient 
facilitates the rational drug choice that would be 
efficacious for that patient. This approach in 
diagnostics and therapeutics brought to the fore 
the dawn of a new trend in the management of 
pain among sickle disease patients based on 
their unique biomarker characteristics, phenotypic 
and pharmacogenetics. This laudable approach 
is referred to as precision medicine (Jameson 
and Longo, 2015). 
 
Application of Pharmacogenomics:  
Indeed, Environmental and genetic factors 
influence many pathophysiological mechanisms 
of SCD that contribute to a highly variable clinical 
expression in individual patients. Pain in SCD is 
classified as acute, chronic, and mixed pain, 
which varies in severity (Ballas et al., 2012; 2015; 
Steinberg et al., 2010). Genetic differences 
appeared to be the major factor for inter-
individual variability in pain perception and 
variable responses to anti-inflammatory and 
opioid drugs (Chou et al., 2006). People who are 
homozygous for 118A>G polymorphism in the 
OPRM1 (a major site of action for most opioid 
analgesics) have more pain and need more 
morphine for management of their pain (Klepstad 
et al., 2004). On the other hand Single-nucleotide 
polymorphisms (SNPs) in the COMT gene affects 
pain sensitivity and low COMT activity may lead 
to increased levels of catecholamine, which 
results in more pain sensitivity (Slade et al., 
2007). 
 




Pharmacogenomics of Pain Susceptibility in 
SCD:  
The initial pain in vasooculusive crisis serve as 
an alert mechanism in response to tissue injury 
which may worsen and persist to a chronic pain 
(Ballas and Lusardi, 2005; Todd et al., 2006). 
Chronic Pain in SCD has a direct impact on the 
quality of life of patients (Kanter and Kruse-
Jarres, 2013). The pain may be associated with 
psychopathology disturbances such as anxiety, 
depression and personality disorder (Dersh et al., 
2002). Several studies on pain perception and 
response to opioids, found that genomic 
variations influence both perception and 
vulnerability to chronic pain (Stamer and Stuber, 
2007). Furthermore, SNPs of specific genes were 
associated with variable degrees of pain 
perception, leading to the hypothesis that some 
variants were located in genes related to the 
inflammatory process of vasoocclusive painful 
crises, resulting in nerve and tissue damage and 
thus the development of secondary pain (Mogil, 
2004; Diatchenko et al., 2005). 
 
It is reported that a polymorphism in the GTP 
cyclohydrolase (GCH1) on chromosome 14 
(rs8007267) among African-Americans, is 
associated with pain crises (Belfer et al., 
2014).This enzyme catalyzes the rate-limiting 
step for tetrahydrobiopterin synthesis, thus 
variation in its gene is likely to have 
pathophysiological roles in pain. Additionally, 
polymorphism of single nucleotide (rs614803) 
located in a region about 8 kb from the COMM 
domain-containing protein COMMD7 is 
significantly associated with painful crises; 
COMMD7 is a modulator of many proteins and is 
associated with NF-kappa-B complex. Similarly, 
genetic studies among Egyptians reported the 
GSTM1 null allele to be significantly associated 
with increased risk of severe vaso-occlusive 
crises (Shiba, 2014). GSTM1 catalyzes the 
addition of glutathione on molecules to increase 
the antioxidant status. Furthermore, there 
reported cases of higher incidence of pain 
observed among SCD patients who were carriers 
of the methylenetetrahydrofolate reductase 
(MTHFR; C677T) polymorphism as well as Factor 
V Leiden (FVL; G191A) polymorphism (Nishank 
et al., 2013). 
 
CONCLUSION 
Management of pain among patients with Sickle 
cell disease can be quiet challenging to both the 
patient and attending clinician. However, the 
growing personalization of medicine predicated 
on the concept of precision medicine, has 
brought about fundamental changes aimed at 
improving the effectiveness and efficiency of 
clinical practice by better understanding how the 
unique biological characteristics of individuals 
and their social and/or environmental contexts 
contribute to their health and disease. For 
instance, in the last century, sickle cell pain was 
treated by guess work through dose escalation or 
reduction of dose of opioids or substitution of one 
analgesic for the other. Now, better 
understanding of opioid receptors structure and 
the role of the CYP450 enzymes in metabolizing 
opioids has revealed that these anatomic and 
metabolic entities are not the same in all persons, 
which explains the variability in response to 
opioids among sickle cell disease patients. 
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